This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Robertson, M. M. Articles by Trimble, M. R. Search for Related Content PubMed Articles by Robertson, M. M. Articles by Trimble, M. R. Social Bookmarking                   What's this?

Risperidone in the treatment of Tourette syndrome: a retrospective case note study

University College London Medical School, Middlesex Hospital Site, Mortimer Street, London W1N8AA, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG

David A. Scull

Institute of Neurology, Queen Square, London WCIN 3BG, UK

Valsamma Eapen

University College London Medical School, Middlesex Hospital Site, Mortimer Street, London W1N8AA

Michael R. Trimble

Institute of Neurology, Queen Square, London WCIN 3BG, UK

Nineteen patients with Tourette syndrome (TS) were treated with risperidone, at a mean daily dose of 1.5 mg. Of those, 41% responded positively, 35% felt that it had made no difference, while it made 24% worse. Although 53% of the patients experienced side-effects, none had extrapyramidal side-effects. At follow-up, 8 to 11 months later, only two of 19 (11 %) patients were still taking risperidone. We suggest that risperidone does have a role in a minority of TS sufferers but it is not suggested as the first line treatment. More placebo-controlled studies using risperidone are clearly indicated.

Key Words: Tourette syndrome • dopamine • 5-HT-2A • risperidone receptors

Journal of Psychopharmacology, Vol. 10, No. 4, 317-320 (1996)
DOI: 10.1177/026988119601000411


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?